Product Description
EPHA1 (Ephrin type-A receptor 1), also known as EPH tyrosine kinase 1, is a member of the receptor tyrosine kinase (RTK) family, specifically the Eph subfamily, that plays a pivotal role in cell migration, tissue boundary formation, axon guidance, and vascular development. EPHA1 binds with high affinity to ephrin-A ligands (such as ephrin-A1, -A2, -A3, -A4, and -A5) anchored to the plasma membrane of adjacent cells, mediating contact-dependent bidirectional signaling. Beyond its role in embryonic development and tissue patterning, dysregulation of EPHA1 signaling is closely associated with tumor progression, metastasis, angiogenesis, and poor prognosis in various cancers including colorectal, breast, ovarian, and hepatocellular carcinoma, making it a highly validated target for cancer therapy and drug discovery.
Screeningbio’s EPHA1 Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying EPHA1 kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: EPHA1 catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the EPHA1 kinase.
Data